IgA Nephropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

IgA Nephropathy Market Outlook

Thelansis’s “IgA Nephropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IgA Nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

IgA Nephropathy Overview

IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide. The fundamental issue of this condition lies in the abnormal glycosylation of O-linked glycans (glycoproteins) within the hinge region of IgA1 throughout the body. Consequently, there are increased galactose-deficient IgA1 (GdIgA1) levels in the bloodstream, targeted by glycan-specific IgA and IgG autoantibodies. IgA, an antibody integral to mucosal immunity, occurs in two isotypes, namely IgA1 and IgA2. It can also exist as a dimeric structure known as secretory IgA. Plasma cells mainly produce secretory IgA in a polymeric form, consisting of multiple monomers linked by the J-chain, a 17-kDa polypeptide. In IgAN, the kidneys sustain the primary damage. The disease follows a gradual yet relentless clinical course, leading to end-stage renal disease (ESRD) in approximately 30-40% of patients within 20-30 years. IgAN can manifest in sporadic cases (90-95%) or familial cases (5-10%). Individuals with familial IgAN may experience a more unfavorable prognosis than those with sporadic forms since they are more likely to progress to renal failure. Currently, there are no FDA-approved treatments for IgAN.

• The annual incidence of IgAN in the United States is 1.29 per 100,000 individuals annually.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: